620604-73-1

Basic information

• Product Name: Benzeneacetonitrile, 4-amino-5-methoxy-2-methyl- (9CI)
• Synonyms: Benzeneacetonitrile, 4-amino-5-methoxy-2-methyl- (9CI);2-(4-AMINO-5-METHOXY-2-METHYLPHENYL)ACETONITRILE
• CAS NO: 620604-73-1
• Molecular Formula: C₁₀H₁₂N₂O
• Molecular Weight: 176.21508
• Product Categories: CYCLOHEXANE
• Mol File: 620604-73-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzeneacetonitrile, 4-amino-5-methoxy-2-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetonitrile, 4-amino-5-methoxy-2-methyl- (9CI)(620604-73-1)
• EPA Substance Registry System: Benzeneacetonitrile, 4-amino-5-methoxy-2-methyl- (9CI)(620604-73-1)

Safety Data

• Hazardous Substances Data: 620604-73-1(Hazardous Substances Data)

Upstream product

• 119-10-8 4-methoxy-3-nitrotoluene 
• 620604-72-0 2-(4-nitro-5-methoxy-2-methylphenyl)acetonitrile 

Relevant articles and documents

POTENT AND SELECTIVE DEGRADERS OF ALK

Disclosed are bispecific compounds (degraders) that target ALK or ALK and FAK for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the bispecific compounds to treat diseases and disorders characterized or mediated by aberrant ALK or ALK and FAK activity.

Diphenyl-aminopyrimidine compound for inhibiting kinase activity

The invention relates to a diphenyl-aminopyrimidine compound with an inhibiting function on protein tyrosine kinase, a pharmaceutical composition containing the diphenyl-aminopyrimidine compound, andpreparation and application of the diphenyl-aminopyrimidine compound, in particular to a compound shown as the formula (I) and pharmaceutically acceptable salt or crystal forms or prodrugs or metabolin or aquo-complex or solvate or isotope derivatives thereof, wherein R1, R2, R5, R6, R7, R8 and W are defined as the description. The compound can be used for treating ALK-mediated cancer related symptoms, such as non-small cell lung cancer or breast cancer or neural tumors or esophagus cancer or soft tissue cancer or lymphoma or leukemia. The formula is shown in the specification.

N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R

The piperidine fragment in ceritinib was replaced with diverse aliphatic amines to improve inherent resistance issues of ceritinib. While most of the prepared compounds exhibit as similar in?vitro activities as ceritinib, compound 10 shows encouraging act

IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES

Compounds of the Formula: where R1-R6 are those defined herein and methods for producing the same. Also provided are pharmaceutical compositions comprising a Compound of Formula I and methods for their use as therapeutic agents.